Subscribe Become an Author Add Company Sign Up Log In

Recursion Pharmaceuticals

Recursion Pharmaceuticals

Private company
RECURSION PHARMACEUTICALS

Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.


Founded
2013
Status
Private company
Geography
United States of America based
Funding
$226.346 M
Patents
3
Research papers
6
Business model
  • Drug Candidate as a Service (DCaaS)
  • Own Drug Discovery Programs
  • Software as a Service / AI as Service (SaaS, AIaaS)
Product type
  • Small molecules
Research focus
  • Biology research (Target identification/validation)
  • Data mining / Ontology building
  • Drug Repurposing
  • Lead Discovery

Investing history

2019Series B121.0
2018Unknown Round0.546
2018Unknown Round20.5
2017Unknown Round4.0
2017Series B60.0
2016Series A2.2
2016Series A12.9
2015Unknown Round0.83
2015Unknown Round1.5
2015Unknown Round2.7
2014Seed round0.17

Press releases

    No mentions found

Posts Mentioning This Company

Biopharma Insights
Biopharma Insights
Drug Discovery Insights

Products

No products posted yet

Services

No services posted yet

Clinical Trials

    No clinical trials found

Patents/applications
  • WO2019178322 (from 2019-09-19), Methods of treating hereditary hemorrhagic telangiectasia and related diseases and methods related thereto
  • WO2019168991 (from 2019-09-06), Systems and methods for discriminating effects on targets
  • WO2018112409 (from 2018-06-21), Methods of treating ataxia-telangiectasia
Publications (PubMed)
  • 30519938 (from 2018-12-07), PREDECT Protocols for Complex 2D/3D Cultures.
  • 30474851 (from 2018-11-27), Methods to Quantify the NF-κB Pathway During Senescence.
  • 30302932 (from 2018-10-12), Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
  • 30066586 (from 2018-08-02), Acid-base regulation in the renal proximal tubules: using novel pH sensors to maintain homeostasis.
  • 27560178 (from 2016-08-26), Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes.
  • 26861901 (from 2016-02-11), Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.

Assets (therapeutic products)

    No assets found

Year Partner Focus Amount of Deal
2016

(2016, Jan. 1)
Sanofi -- --
2017

(2017, Jan. 1)
Takeda -- $ 90.0 M